Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transth

Indication
Cardiomyopathies; Heart Diseases; Amyloidosis

Other upcoming events for BBIO

Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Sympto
Phase 3 ReadoutPhase 3 Topline: A Phase 2/3, Multicenter, Single-Arm, Open-Label Study Evaluating the Pharmacokinetics, Efficacy, an
Patent ExpiryPatent/Exclusivity Expiry: TRUSELTIQ
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed V

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transth — BBIO Phase 3 Readout | BioSniper